Kiadis Pharma appoints Dr. Robert Friesen... Kiadis Pharma N.V., a clinical-stage biopharmaceutical company, on Monday announced the appointment of Robert Friesen, PhD as Chief Scientific Officer (CSO) effective February 1, 2019. more ➔
Rentschler Biopharma SE appoints Dr. Chris... Rentschler Biopharma SE announced today the appointment of Dr. Christian Hunzinger as the new Senior Vice President Project Management, effective from January 15, 2019. more ➔
Valbiotis appoints Josep Infesta Valbiotis, a French research and development company committed to preventing and combating metabolic diseases, today on 24 January the appointment of Josep Infesta as Head of Global Business Development. more ➔
Asceneuron appoints Peter Van Vlasselaer Asceneuron, a company in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as … more ➔
Pharnext announces two appointments Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medical Officer. more ➔
Immuno-Oncology experts to join Protagen A... Protagen AG, a precision medicine specialist at the forefront of immuno-profiling, announced today the appointment of Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, … more ➔
Immunocore appoints Bahija Jallal as CEOImmunocore has appointed Bahija Jallal as Chief Executive Officer and Director of the Board. more ➔
Gilead names Daniel ODay CEO Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel ODay Chairman of the Board and Chief Executive Officer, effective March 1, 2019. Mr. ODay … more ➔
Genentech CEO to switch to Roche Pharma William Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019. He will be based in Basel, report to Severin Schwan, Roche Group CEO and become a … more ➔
Forbion appoints Dr. Carlo Incerti as Oper... Forbion, a European life science venture capital firm, today announces that Carlo Incerti, M.D., will be joining Forbion as Operating Partner, effective 1st January 2019. more ➔
